[ Ссылка ]

ORLANDO -- Prasugrel, a third-generation thienopyridine, reduced myocardial infarction, stroke, and cardiovascular mortality compared with clopidogrel (Plavix) in a trial of acute coronary syndrome patients, but it failed to come away with a clear victory.

In this exclusive MedPage Today report, Peggy Peck and Greg Laub present the many sides of TRITON-TIMI 38 in interviews with investigators and leading cardiologists.

Medpage Today: [ Ссылка ]
Online CME - Continuing medical education: [ Ссылка ]
Latest medical news: [ Ссылка ]

The MedPage Today app:
iOS: [ Ссылка ]
Android: [ Ссылка ]

MedPage Today Youtube Channel: [ Ссылка ]
Medpage Today on Facebook: [ Ссылка ]

свернуть